Mapping the Alzheimer’s Disease Cooperative Study-Activities of Daily Living Inventory to the Health Utility Index Mark III

Cheung, Yin Bun; Tan, Hui Xing; Wang, Vivian Wei; Kandiah, Nagaendran; Luo, Nan; Koh, Gerald; Wee, Hwee Lin

doi:10.1007/s11136-018-1991-4

Cited by 6 publications

(10 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A study that compared the use of the dementia-specific QoL-AD and the general instrument HUI3 found that HUI3 results had a stronger correlation with other outcome measures, including functional abilities, cognition, dependence, and behavior, than the QoL-AD [ 56 ]. Other researchers have noted that while it is a general instrument, the HUI3 includes domains such as speech and cognition that are important for patients with dementia [ 57 ].…”

Section: Resultsmentioning

confidence: 99%

The Humanistic and Economic Burden of Alzheimer's Disease

et al. 2022

View full text Add to dashboard Cite

Alzheimer's disease (AD) is the leading cause of cognitive impairment and dementia in older individuals (aged C 65 years) throughout the world. As a result of these progressive deficits in cognitive, emotional, and physical function, AD dementia can cause functional disability and loss of independence. To gain a deeper understanding of the recent literature on the burden of AD, including that of mild cognitive impairment (MCI) due to AD, we conducted a comprehensive targeted review of the PubMedindexed literature (2014 to 2021) to examine the humanistic and economic burden of AD (including MCI) in North America, Europe, and Asia. Our literature review identified a range of factors associated with quality of life (QoL): some factors were positively associated with QoL, including caregiver relationship, religiosity, social engagement, and ability to engage in activities of daily living (ADL), whereas other factors such as neuropsychiatric symptoms were associated with poorer QoL. While patient-and proxy-rated QoL are highly correlated in patients with early AD dementia, proxy-rated QoL declines more substantially as severity worsens. The maintenance of self-reported QoL in patients with more severe AD dementia may be due to lack of awareness or to adaptation to circumstances. Compared to persons with normal cognition, MCI is associated with a greater cost burden, and individuals with MCI exhibit worse QoL. Key drivers of the societal economic burden of AD include disease severity, dependence level, institutionalization, and comorbidity burden. Evaluation of the impact of a hypothetical disease-modifying treatment delaying the progression from MCI to AD has suggested that such a treatment may result in cost savings.

show abstract

Section: Resultsmentioning

confidence: 99%

The Humanistic and Economic Burden of Alzheimer's Disease

et al. 2022

View full text Add to dashboard Cite

show abstract

“…There are other regression-based methods, such as the Tobit regression and indirect mapping by multinomial logistic regression [7, 18]. These regression methods do not consistently perform better than the OLS [7, 17, 19].…”

Section: Discussionmentioning

confidence: 99%

“…It is well known that OLS mapping under-estimates variability and therefore inflates type 1 errors [5]. Furthermore, OLS mapping tends to under-estimate the health utility of people in good health states and over-estimate it among people in bad health states, which leads to under-estimates of the incremental cost-utility ratio [15, 19–21].…”

Section: Introductionmentioning

confidence: 99%

“…Smoothing health utility and patient reported outcome data is not a simple task. In particular, these measures often have a substantial ceiling effect, which is known to create extra difficulties for smoothing [19–21, 23].…”

Section: Introductionmentioning

confidence: 99%

“…One study has mapped the World Health Organization Quality of Life – Brief to the EQ-5D-5 L [21] and another study has mapped the Functional Assessment of Cancer Therapy – Breast (FACT-B) to the EQ-5D-5 L [20] using MRM. Furthermore, the Alzheimer’s Disease Cooperative Study-Activities of Daily Living Inventory (ADCS-ADL) has also been mapped to the Health Utility Index Mark III by the MRM [19]. All three studies demonstrated good performance properties of the MRM at the group level.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Mapping the medical outcomes study HIV health survey (MOS-HIV) to the EuroQoL 5 Dimension (EQ-5D-3 L) utility index

Yuan

Thompson

Walker

et al. 2019

Health Qual Life Outcomes

Self Cite

View full text Add to dashboard Cite

Background Mapping of health-related quality-of-life measures to health utility values can facilitate cost-utility evaluation. Regression-based methods tend to lead to shrinkage of variance. This study aims to map the Medical Outcomes Study HIV Health Survey (MOS-HIV) to EuroQoL 5 Dimensions (EQ-5D-3 L) utility index, and to characterize the performance of three mapping methods, including ordinary least squares (OLS), equi-percentile method (EPM), and a recently proposed method called Mean Rank Method (MRM). Methods This is a secondary analysis of data from a randomized HIV treatment trial. Baseline data from 421 participants were used to develop mapping functions. Follow-up data from 236 participants was used to validate the mapping functions. Results In the training dataset, MRM and OLS, but not EPM, reproduced the observed mean utility (0.731). MRM, OLS and EPM under-estimated the standard deviation by 0.3, 26.6 and 1.7%, respectively. MRM had the lowest mean absolute error (0.143) and highest intraclass correlation coefficient (0.723) with the observed utility values, whereas OLS had the lowest mean squared error (0.038) and highest R-squared (0.542). Regressing the MRM- and OLS-mapped utility values upon body mass index and log-viral load gave covariate associations comparable to those estimated from the observed utility data (all P > 0.10). EPM did not achieve this property. Findings from the validation data were similar. Conclusions Functions are available for mapping the MOS-HIV to the EQ-5D-3 L utility values. MRM and OLS were comparable in terms of agreement with the observed utility values at the individual level. MRM had better performance at the group level in terms of describing the utility distribution. Trial registration NCT00988039 . Registered 30 September 2009. Electronic supplementary material The online version of this article (10.1186/s12955-019-1135-8) contains supplementary material, which is available to authorized users.

show abstract

Alzheimer's and Parkinson's disease therapies in the clinic

Chopade

Zhao

et al. 2022

Bioengineering & Transla Med

View full text Add to dashboard Cite

Alzheimer's disease (AD) and Parkinson's disease (PD) are the most prevalent neurodegenerative diseases, affecting millions and costing billions each year in the United States alone. Despite tremendous progress in developing therapeutics that manage the symptoms of these two diseases, the scientific community has yet to develop a treatment that effectively slows down, inhibits, or cures neurodegeneration. To gain a better understanding of the current therapeutic frontier for the treatment of AD and PD, we provide a review on past and present therapeutic strategies for these two major neurodegenerative disorders in the clinical trial process. We briefly recap currently US Food and Drug Administration‐approved therapies, and then explore trends in clinical trials across the variables of therapy mechanism of disease intervention, administration route, use of delivery vehicle, and outcome measures, across the clinical phases over time for “Drug” and “Biologic” therapeutics. We then present the success rate of past clinical trials and analyze the intersections in therapeutic approaches for AD and PD, revealing the shift in clinical trials away from therapies targeting neurotransmitter systems that provide symptomatic relief, and towards anti‐aggregation, anti‐inflammatory, anti‐oxidant, and regeneration strategies that aim to inhibit the root causes of disease progression. We also highlight the evolving distribution of the types of “Biologic” therapies investigated, and the slowly increasing yet still severe under‐utilization of delivery vehicles for AD and PD therapeutics. We then briefly discuss novel preclinical strategies for treating AD and PD. Overall, this review aims to provide a succinct overview of the clinical landscape of AD and PD therapies to better understand the field's therapeutic strategy in the past and the field's evolution in approach to the present, to better inform how to effectively treat AD and PD in the future.

show abstract

Mapping the Alzheimer’s Disease Cooperative Study-Activities of Daily Living Inventory to the Health Utility Index Mark III

Abstract: The MRM is accurate at the group level. The regression-based mapping methods are more accurate for making individual-level prediction. In addition, CLAD also performed reasonably well at the group level.

Cited by 6 publications

References 33 publications

The Humanistic and Economic Burden of Alzheimer's Disease

The Humanistic and Economic Burden of Alzheimer's Disease

Mapping the medical outcomes study HIV health survey (MOS-HIV) to the EuroQoL 5 Dimension (EQ-5D-3 L) utility index

Alzheimer's and Parkinson's disease therapies in the clinic

Contact Info

Product

Resources

About